company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6182000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5586000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11768000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11746000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,191000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,34000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-157000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11903000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11903000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11903000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11903000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47225000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47225000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 16:22:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47225000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,308000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,308000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,308000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6624000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8186000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14810000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14502000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,165000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,21000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-144000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14646000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14646000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14646000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14646000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,47440000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,47440000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2010.0,Q3,2010-07-01,2010-09-30,2011-11-08 16:15:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,47440000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5204000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3131000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8335000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7478000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,101000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,11000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-90000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7568000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7568000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7568000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7568000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,48082000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,48082000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q2,2011-04-01,2011-06-30,2012-08-09 08:03:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48082000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3907000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1539000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5446000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4589000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,9000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,9000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4580000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4580000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4580000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4580000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,48085000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,48085000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 19:58:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48085000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4512000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6800000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11312000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10455000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,43000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,41000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10414000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10414000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10414000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10414000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,65989000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,65989000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q1,2012-01-01,2012-03-31,2012-05-10 06:13:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,65989000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4742000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12822000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17564000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16707000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,46000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,46000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16661000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16661000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16661000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16661000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,67780000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,67780000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 21:28:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,67780000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1714000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1714000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1714000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5082000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,28252000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-30600000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,64791000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32477000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,22000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-30600000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,58000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-63019000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-63019000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,30564000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32455000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,30564000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-63019000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70739000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70739000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70739000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5100000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15155000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20255000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19398000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,31000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,30000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19368000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19368000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19368000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19368000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,90336000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,90336000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q1,2013-01-01,2013-03-31,2013-05-09 14:16:05+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,90336000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6026000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13094000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19120000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18263000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,17000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,17000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18246000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18246000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18246000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18246000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,94986000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,94986000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 17:13:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,94986000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1714000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1714000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1714000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6341000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15472000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-18581000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41251000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20956000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,538000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-18580000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-520000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-40057000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40057000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,18572000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21485000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,18572000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-40057000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,96491000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,96491000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,96491000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7010000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17001000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24011000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23154000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1770000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,26000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1744000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24898000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24898000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24898000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24898000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,108300000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,108300000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.23
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,109249000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q1,2014-01-01,2014-03-31,2015-05-08 12:11:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6933000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16726000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23659000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22802000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1731000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,26000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1705000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24507000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24507000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24507000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24507000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,117987000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,117987000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q2,2014-04-01,2014-06-30,2014-08-08 17:13:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,117987000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,30857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,30857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,30857000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7097000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10719000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17816000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,13041000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1784000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,16000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1768000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,11273000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,11273000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,11273000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,11273000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,122583000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q3,2014-07-01,2014-09-30,2014-11-10 13:47:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,130140000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22950000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22950000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22950000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7599000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12966000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20565000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2385000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1798000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,20000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1778000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,607000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,607000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,607000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,607000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11800000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.94
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11800000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.94
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11824000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.94
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4359000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4359000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4359000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8584000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11242000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19826000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15467000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1829000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,63000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1766000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17233000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17233000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17233000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17233000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,123100000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,123100000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,123884000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q1,2015-01-01,2015-03-31,2015-05-08 12:11:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5194000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5194000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5194000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10815000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15107000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25922000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20728000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1843000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,67000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1776000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22504000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22504000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22504000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22504000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,12500000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.8
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12500000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.8
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,12519000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 14:20:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.8
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9974000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9974000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9974000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12103000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8817000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20920000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10946000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1872000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,65000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1612000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-195000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11141000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11141000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11141000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11141000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,12975000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.86
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,12975000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.86
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13000000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 21:42:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.86
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4932000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4932000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4932000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12260000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5584000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17844000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12912000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1902000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,32000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1651000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3521000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16433000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1376000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17809000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17809000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17809000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,132100000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.28
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,132100000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.28
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,131129000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.28
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5033000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5033000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5033000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,16551000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11801000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28352000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23319000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1936000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,123000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2784000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,971000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22348000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22348000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22348000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22348000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14500000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.54
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14500000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.54
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14556000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q1,2016-01-01,2016-03-31,2017-05-11 18:10:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.54
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7791000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7791000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1784000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1784000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6007000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,24991000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14249000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39240000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33233000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1954000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,163000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,9794000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,8003000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-25230000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25230000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25230000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-25230000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14600000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.73
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14600000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.73
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14566000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q2,2016-04-01,2016-06-30,2016-08-05 14:20:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.73
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7002000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7002000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1940000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1940000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5062000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,35103000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5254000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1408000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-80229000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,1000000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-37464000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,42526000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1988000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,239000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,6886000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5137000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,47663000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,47663000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,47663000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,47663000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14587000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,3.27
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36615000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.12
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14600000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q3,2016-07-01,2016-09-30,2016-11-04 21:42:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.27
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13883000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13883000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4271000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4271000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9612000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,41938000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6719000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1899000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,2000000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,52556000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-42944000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-16315000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,97000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2056000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,18468000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24476000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,133000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24609000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24609000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24609000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14600000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.68
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14600000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.47
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14576000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.68
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19145000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19145000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6187000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6187000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12958000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,55247000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8173000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1984000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,1400000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,66804000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-53846000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-11143000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,147000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-26531000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-15241000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-69087000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-69087000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-69087000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-69087000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14800000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-4.67
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14800000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-4.67
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,14806000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q1,2017-01-01,2017-03-31,2017-05-11 18:10:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-4.67
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23356000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23356000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6842000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6842000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16514000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,48311000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7509000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1984000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,700000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,58504000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-41990000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,863000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,117000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,12218000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,11472000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30518000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30518000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30518000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30518000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15300000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15300000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15237000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q2,2017-04-01,2017-06-30,2017-08-09 06:04:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18903000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18903000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4037000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4037000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14866000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,30367000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5776000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,1985000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-500000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37628000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22762000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,794000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,180000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2547000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1933000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20829000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20829000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20829000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20829000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15440000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.35
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15440000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.35
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15400000.0
Orexigen Therapeutics Inc,OREX,5493008EJF1IXC1DOC52,0001382911,2017.0,Q3,2017-07-01,2017-09-30,2017-11-13 19:56:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.35
